Camrelizumab, previously known as SHR-1210, represents a significant advancement in tumor immune therapy , functioning as a antibody that inhibits the programmed cell death 1 receptor. This regulatory https://opensocialfactory.com/story25822444/camrelizumab-shr-1210-a-deep-analysis-into-the-anti-pd-1-therapy